- Home
- ZTEK vs LUCD Comparison
ZTEK vs LUCD Comparison
Compare ZTEK & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | LUCD |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | LUCD |
|---|---|---|
| Price | $0.72 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.94 |
| AVG Volume (30 Days) | 41.9K | ★ 709.8K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $657,134.00 | ★ $4,399,000.00 |
| Revenue This Year | N/A | $12.31 |
| Revenue Next Year | N/A | $152.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2225.73 | 5.01 |
| 52 Week Low | $0.62 | $0.75 |
| 52 Week High | $1.84 | $1.80 |
Technical Indicators
Market Signals| Indicator | ZTEK | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 61.67 |
| Support Level | $0.70 | $1.02 |
| Resistance Level | $0.75 | $1.16 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 0.83 | 100.00 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.